These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36962785)

  • 1. Understanding barriers and facilitators to clinic attendance and medication adherence among adults with hypertensive urgency in Tanzania.
    Kisigo GA; Mcharo OC; Robert JL; Peck RN; Sundararajan R; Okello ES
    PLOS Glob Public Health; 2022; 2(8):e0000919. PubMed ID: 36962785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peer Counselor Intervention for Reducing Mortality and/or Hospitalization in Adults With Hypertensive Urgency in Tanzania: A Pilot Study.
    Kisigo GA; Mgeta F; Mcharo O; Okello E; Wajanga B; Kalokola F; Mtui G; Sundararajan R; Peck RN
    Am J Hypertens; 2023 Jul; 36(8):446-454. PubMed ID: 37086189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model.
    Holtzman CW; Shea JA; Glanz K; Jacobs LM; Gross R; Hines J; Mounzer K; Samuel R; Metlay JP; Yehia BR
    AIDS Care; 2015; 27(7):817-28. PubMed ID: 25671515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertensive Urgency in Tanzanian Adults: A 1-Year Prospective Study.
    Reis KG; Wilson R; Kalokola F; Wajanga B; Lee MH; Safford M; Peck RN
    Am J Hypertens; 2020 Dec; 33(12):1087-1091. PubMed ID: 32776154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and healthcare provider perspectives on adherence with antihypertensive medications: an exploratory qualitative study in Tanzania.
    Edward A; Campbell B; Manase F; Appel LJ
    BMC Health Serv Res; 2021 Aug; 21(1):834. PubMed ID: 34407820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme.
    Krummenacher I; Spencer B; Du Pasquier S; Bugnon O; Cavassini M; Schneider MP
    Int J Clin Pharm; 2014 Aug; 36(4):716-24. PubMed ID: 24913358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to Antihypertensive Medication: An Interview Analysis of Southwest Ugandan Patients' Perspectives.
    Najjuma JN; Brennaman L; Nabirye RC; Ssedyabane F; Maling S; Bajunirwe F; Muhindo R
    Ann Glob Health; 2020 Jun; 86(1):58. PubMed ID: 32897274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study.
    Ho SC; Jacob SA; Tangiisuran B
    PLoS One; 2017; 12(6):e0179290. PubMed ID: 28614368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study.
    Ogedegbe G; Harrison M; Robbins L; Mancuso CA; Allegrante JP
    Ethn Dis; 2004; 14(1):3-12. PubMed ID: 15002917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment.
    Liu Q; Abba K; Alejandria MM; Sinclair D; Balanag VM; Lansang MA
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD006594. PubMed ID: 25403701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.
    Versfeld A; McBride A; Scheibe A; Spearman CW
    Harm Reduct J; 2020 Jun; 17(1):39. PubMed ID: 32522210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doubts, denial and divine intervention: understanding delayed attendance and poor retention rates at a HIV treatment programme in rural Tanzania.
    Wringe A; Roura M; Urassa M; Busza J; Athanas V; Zaba B
    AIDS Care; 2009 May; 21(5):632-7. PubMed ID: 19444672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers and facilitators to ART adherence among ART non-adherence people living with HIV in Cameroon: A qualitative phenomenological study.
    Buh A; Deonandan R; Gomes J; Krentel A; Oladimeji O; Yaya S
    PLoS One; 2023; 18(9):e0291487. PubMed ID: 37699048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitators and barriers to antiretroviral therapy adherence among HIV-positive adolescents living in Tanzania.
    Audi C; Jahanpour O; Antelman G; Guay L; Rutaihwa M; van de Ven R; Woelk G; Baird SJ
    BMC Public Health; 2021 Dec; 21(1):2274. PubMed ID: 34903209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving treatment adherence for blood pressure lowering via mobile phone SMS-messages in South Africa: a qualitative evaluation of the SMS-text Adherence SuppoRt (StAR) trial.
    Leon N; Surender R; Bobrow K; Muller J; Farmer A
    BMC Fam Pract; 2015 Jul; 16():80. PubMed ID: 26137844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers and facilitators of people living with HIV receiving optimal care for hypertension and diabetes in Tanzania: a qualitative study with healthcare professionals and people living with HIV.
    Gooden TE; Mkhoi ML; Mdoe M; Mwalukunga LJ; Senkoro E; Kibusi SM; Thomas GN; Nirantharakumar K; Manaseki-Holland S; Greenfield S
    BMC Public Health; 2023 Nov; 23(1):2235. PubMed ID: 37957584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence in Type 2 Diabetes Mellitus: A Qualitative Exploration of Barriers and Facilitators From Socioecological Perspectives.
    Onwuchuluba EE; Oyetunde OO; Soremekun RO
    J Patient Exp; 2021; 8():23743735211034338. PubMed ID: 34368436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying barriers and facilitators along the hepatitis C care cascade to inform human-centered design of contextualized treatment protocols for vulnerable populations in Austin, Texas: a qualitative study.
    Desai A; O'Neal L; Reinis K; Brown C; Stefanowicz M; Kuang A; Agrawal D; Bhavnani D; Mercer T
    Implement Sci Commun; 2023 Aug; 4(1):98. PubMed ID: 37592306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the theoretical domains framework to determine the barriers and facilitators to medication adherence in Parkinson's disease.
    Smith JC; Seage CH; Lane E; James DH
    Explor Res Clin Soc Pharm; 2023 Sep; 11():100309. PubMed ID: 37583935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis.
    Voshaar MJH; van den Bemt BJF; van de Laar MAFJ; van Dulmen AM; Vriezekolk JE
    BMC Health Serv Res; 2022 Jan; 22(1):62. PubMed ID: 35022034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.